Sökresultat - Cunshan Wang

Förfina resultatet
  1. 1
    Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model

    Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model av Robert S. Wallis, Cunshan Wang, Daniel Meyer, Neal Thomas

    Publicerad 2013
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  2. 2
    Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease

    Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease av Sriram Krishnaswami, Vincent Chow, M. Boy, Cunshan Wang, Gary Chan

    Publicerad 2013
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials

    Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials av Alan Kivitz, Oliver FitzGerald, Peter Nash, Shirley Pang, Valderílio Feijó Azevedo, Cunshan Wang, Liza Takiya

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab

    Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab av Désirée van der Heijde, Dafna D. Gladman, Oliver FitzGerald, Arthur Kavanaugh, Daniela Graham, Cunshan Wang, Lara Fallon

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

    Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance av Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose L. Rivas, Birgitta Benda

    Publicerad 2023
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS

    AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS av William F. C. Rigby, Gerd R Burmester, Oliver FitzGerald, Valderílio Feijó Azevedo, Peter Nash, Daniela Graham, Cunshan Wang, Thomas V. Jones

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

    Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis av M. Boy, Cunshan Wang, Bethanie Wilkinson, Vincent Fung-Sing Chow, Alan Clucas, James G. Krueger, Anderson S. Gaweco, Samuel H. Zwillich, Paul S. Changelian, Gary Chan

    Publicerad 2009
    Hämta fulltext
    Carta
    Lägg till i favoriter
    Sparad:
  8. 8
    Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

    Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial av Kim Papp, Robert Bissonnette, Melinda Gooderham, Steven R. Feldman, Lars Iversen, Jennifer Soung, Zoe Diana Draelos, Carla Mamolo, Vivek S. Purohit, Cunshan Wang, William C. Ports

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

    Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies av Peter Nash, Laura C. Coates, Roy Fleischmann, Kim Papp, Juan J. Gómez‐Reino, Keith S. Kanik, Cunshan Wang, Joseph Wu, Sujatha Menon, Thijs Hendrikx, William C. Ports

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  10. 10
    Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

    Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors av Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth M. Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S. Kanik

    Publicerad 2017
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con... av Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip J. Mease, Dafna D. Gladman, Daniela Graham, Cunshan Wang, Joseph C. Cappelleri, Thijs Hendrikx, Ming‐Ann Hsu

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

    Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis av Philip J. Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F. Merola, Francisco Ávila‐Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S. Kanik

    Publicerad 2017
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase <scp>III</scp> and Long‐Term Extension Studies

    Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase <scp>III</scp> a... av Dafna D. Gladman, Christina Charles‐Schoeman, Iain B. McInnes, Douglas J. Veale, B.H. Thiers, Michael T. Nurmohamed, D. Graham, Cunshan Wang, Thomas V. Jones, Robert Wołk, Ryan DeMasi

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  14. 14
    Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial

    Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, d... av Victoria Navarro‐Compán, James Cheng‐Chung Wei, Filip Van den Bosch, Marina Magrey, Lisy Wang, Dona Fleishaker, Joseph C. Cappelleri, Cunshan Wang, Joseph Wu, Oluwaseyi Dina, Lara Fallon, Vibeke Strand

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  15. 15
    Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

    Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study av Atul Deodhar, Paula Śliwińska-Stańczyk, Huji Xu, Xenofon Baraliakos, Lianne S. Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S. Kanik, Désirée van der Heijde

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  16. 16
    Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

    Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial av Jeffrey R. Curtis, Kunihiro Yamaoka, Yi‐Hsing Chen, Deepak L. Bhatt, Levent M Gunay, Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranić, Juan J. Gómez‐Reino

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  17. 17
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis av Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls, Gary G. Koch, R. Fleischmann, Jose L. Rivas, Rebecca Germino, Sujatha Menon, Yanhui Sun, Cunshan Wang, Andrea Shapiro, Keith S. Kanik, Carol A. Connell

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  18. 18
    An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

    An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data av Gerd R Burmester, Jeffrey R. Curtis, Huifeng Yun, Oliver FitzGerald, Kevin Winthrop, Valderílio Feijó Azevedo, William F. C. Rigby, Keith S. Kanik, Cunshan Wang, Pinaki Biswas, Thomas V. Jones, Niki Palmetto, Thijs Hendrikx, Sujatha Menon, Ricardo Rojo

    Publicerad 2020
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  19. 19
    Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

    Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study av Peter Nash, Laura C. Coates, Alan Kivitz, Philip J. Mease, Dafna D. Gladman, Jose A Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu, Ming‐Ann Hsu, Sujatha Menon, Lara Fallon, Ana Belén Romero, Keith S. Kanik

    Publicerad 2020
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  20. 20
    Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

    Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atheroscler... av Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg, Gary G. Koch, Ivana Vranić, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L. Rivas, Arne Yndestad, Carol A. Connell, Zoltán Szekanecz

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: